简介: 是一种可口服的非酸类抗炎剂,为有效的、选择性的 COX-2 抑制剂,同时是活性代谢物 6MNA 的前体物质。。
别名:Nabumetone
物理性状及指标:
外观:……………………白色结晶性粉末
熔点:……………………80〜83℃
溶解性:…………………乙醇:25mg/ml;Water Insoluble
含量:……………………≥99%
储存条件: 常温,避光防潮密闭干燥
生物活性 (仅来自于公开文献)
产品描述 |
Nabumetone is an orally active non-acidic anti-inflammatory agent, acts as a potent and selective COX-2 inhibitor, and is the prodrug of the active metabolite 6MNA. |
|
靶点 |
|
|
体外研究 |
Nabumetone is a potent and selective COX-2 inhibitor. Nabumetone (50 μmol-2 mmol) dose-dependently inhibits the proliferation of K-562 and Meg-01 cells, but shows no obvious apoptotic effect. Nabumetone potentiates the apoptotic effect of ADR in the K-562 cell line. Moreover, Nabumetone reduces Bcl-2 expression. |
|
体内研究 |
Nabumetone (79 mg/kg, p.o.) inhibits paw oedema and paw exudate PGE2 in rats. Nabumetone does not induce gastric damage and causes only 57% inhibition of gastric mucosal 6-keto-PGF1α production in rats. Nabumetone (25, 50, 100 mg/kg, i.p.) dose-dependently inhibits the increase of DDC-induced mucus secretion and stimulates stress-induced mucus secretion in rats. Nabumetone (25 mg/kg, i.p.) significantly suppresses stress-induced ulcer index in rats. |
用途及描述:科研试剂,广泛应用于分子生物学,药理学等科研方面,严禁用于人体。本品为非甾体抗炎化合物。具有抗炎、解热和镇痛作用。其作用机理可能是通过阻断环氧合酶的活性,从而抑制了前列腺素(PG)的合成。
储液配置:
浓度/体积(DMSO)/质量 |
1 mg |
5 mg |
10 mg |
1 mM |
3.4801 mL |
17.4004 mL |
34.8008 mL |
5 mM |
0.6960 mL |
3.4801 mL |
6.9602 mL |
10 mM |
0.3480 mL |
1.7400 mL |
3.4801 mL |
50 mM |
0.0696 mL |
0.3480 mL |
0.6960 mL |
【注意】
●我司产品为非无菌包装,若用于细胞培养,请提前做预处理,除去热原细菌,否则会导致染菌。
●部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,以上数据仅供参考交流研究之用。
我司所售出产品仅供于科研研究用途(非临床科研研究),每次销售产品行为都适用于我司网上所列明的。
质量标准:≥99%
TESTS |
SPECIFICATIONS |
Appearance |
White crystalline powder |
Identification |
UV |
Solubility |
25mg/ml EtOH ,clear |
M.P |
80〜83℃ |
Purity (HPLC) |
≥99% |